受体酪氨酸激酶AXL在肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2017.03.019

Abstract

Abstract: AXL is a member of the TAM receptor tyrosine kinase family,and AXL has been shown to be associated with a variety of cancers such as lung cancer,breast cancer,thyroid cancer,prostate cancer and pancreatic cancer.The latest evidence suggests that AXL can promote the growth,invasion and metastasis of various tumors,and its inhibitors can also inhibit tumor formation,suggesting that AXL may be a potential target for anti-tumor therapy,and the use of AXL kinase inhibitors may become the new strategy of anti-tumor therapy.This article reviews the progress of AXL and tumor.

Key words: Receptor tyrosine kinase, AXL, Tumor, AXL kinase inhibitors

CLC Number:

TANG Xiaosong,CHEN Gongyan. Research progress of receptor tyrosine kinase AXL in tumor[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 281-284.

References

1 Mukherjee SK,Wilhelm A,Antoniades CG.TAM receptor tyrosine kinase function and the immunopathology of liver disease[J].Am J Physiol Gastrointest Liver Physiol,2016,310(11):899-905.
2 Graham DK,DeRyckere D,Davies KD,et al.The TAM family:phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer[J].Nat Rev Cancer,2014,14(12):769-785.
3 Subramanian M,Hayes CD,Thome JJ,et al.An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo[J].J Clin Invest,2014,124(3):1296-1308.
4 Meyer AS,Zweemer AJ,Lauffenburger DA.The AXL Receptor is a sensor of ligand spatial heterogeneity[J].Cell Syst,2015,1(1):25-36.
5 Levin PA,Brekken RA,Byers LA,et al.AXL receptor axis:A new therapeutic target in lung cancer[J].Thorac Oncol,2016,11(8):1357-1362.
6 Li Y,Ye X,Tan C,et al.AXL as a potential therapeutic target in cancer:role of AXL in tumor growth,metastasis and angiogenesis[J].Oncogene,2009,28(39):3442-3455.
7 Paolino M,Choidas A,Wallner S,et al.The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells[J].Nature,2014,507(7493):508-512.
8 Wu F,Li J,Jang C,et al.The role of AXL in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma[J].Int J Clin Exp Pathol,2014,7(10):6653-6661.
9 Scaltriti M,Elkabets M,Baselga J.Molecular pathways:AXL,a membrane receptor mediator of resistance to therapy[J].Clin Cancer Res,2016,22(6):1313-1317.
10 Sawabu T,Seno H,Kawshiima T,et al.Growth arrest-specific gene 6 and signaling enhances gastric cancer cell survival via Akt pahway[J].Mol Carcino,2007,46(2):155-164.
11 Cackowski FC,Eber MR,Rhee J,et al.Mer tyrosine kinase regulates disseminated prostate cancer cellular dormancy[J].J Cell Biochem,2016,9999:1-12.
12 Yung Y,Decker AM,Wang J,et al.Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow[J].Oncotarget,2016,7(18):25698-25711.
13 Cui ZL,Han FF,Peng XH,et al.YES-associated protein 1 promotes adenocarcinoma growth and metastasis through activation of the receptor tyrosine kinase AXL[J].Int J Immunopathol Pharmacol,2012,25(4):989-1001.
14 Choi YJ,Kim SY,So KS,et al.AUY922 effectively overcomes MET-and AXL-mediated resistance to EGFR-TKI in lung cancer cells[J].PLoS One,2015,10(3):e0119832.
15 Zhang YX,Knyazev PG,Cheburkin YV,et al.AXL is a potential target for therapeutic intervention in breast cancer progression[J].Cancer Res,2008,68(6):1905-1915.
16 Mudduluru G,Ceppi P,Kumarswamy R,et al.Regulation of AXL receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer[J].Oncogene,2011,30(25):2888-2899.
17 Wang XP,Saso H,Iwamoto T,et al.TIG1 Promotes the development and progression of inflammatory breast cancer through activation of AXL kinase[J].Cancer Res,2013,73(21):6516-6525.
18 Paccez JD,Vasques GJ,Correa RG,et al.The receptor tyrosine kinase AXL is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target[J].Oncogene,2013,32(6):689-698.
19 Wilson C,Ye X,Pham T,et al.AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs[J].Cancer Res,2014,74(20):5878-5890.
20 Byers LA,Diao L,Wang J,et al.An epithelial mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies AXL as a therapeutic target for overcoming EGFR inhibitor resistance[J].Clin Cancer Res,2013,19(1):279-290.
21 Scaltriti M,Elkabets M,Baselga J.Molecular pathways:AXL,a membrane receptor mediator of resistance to therapy[J].Clin Cancer Res,2016,22(6):1313-1317.
22 Wu W,Bi C,Credille KM,et al.Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653,an inhibitor of several oncokinases,including MET[J].Clin Cancer Res,2013,19(20):5699-5710.
23 Burbridge MF,Bossard CJ,Saunier C,et al.S49076 Is a novel kinase inhibitor of MET,AXL,and FGFR with strong preclinical activity alone and in association with bevacizumab[J].Mol Cancer Ther,2013,12(9):1749-1762.
24 Myers SH,Brunton VG,Unciti-Broceta A.AXL inhibitors in cancer:a medicinal chemistry perspective[J].Med Chem,2015,59(8):3593-3608.
25 Sheridan C.First AXL inhibitor enters clinical trials[J].Nat Biotechnol,2013,31(9):775-776.
26 Esposito CL,Cerchia L,Catuogno S,et al.Multifunctional aptamer-miRNA conjugates for targeted cancer therapy[J].Mol Ther,2014,22(6):1151-1163.
27 安然,胡博,郎小玲,等.靶向AXL 药物在癌症治疗中的研究进展[J].国际药学研究杂志,2016,43(3):420-424.

[1]	ZHANG Maoxiang,SUN Huixin,SONG Bingbing. Analysis of the incidence and mortality of malignant tumors in Daoli District,Harbin,2008—2012 [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 261-265.
[2]	LIU Yishu,QU Guofan. Progress in long-chain non-coding RNA in osteosarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 266-270.
[3]	HOU Yuxue,LI Xiaoli. The research progress of Wnt7a and malignant tumors,and its relationship [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 271-275.
[4]	XU Hui, LI Xi, ZHOU Chunshui. Screening of lung cancer tumor-associated suppressor genes using shRNA library targeting human transcriptome [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 97-102.
[5]	YUAN Guixia, LI Yan, FENG Wanqi, XIA Xiaojuan, LI Xu. Mechanism of tumor suppressor gene DKK2 inhibiting proliferation of nephroblastoma cells in children [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 14-20.
[6]	DING Jiexian, ZHANG Jin, CHEN Yonggang, WANG Xingwen, WANG Shuanke. Progress in Wnt signaling pathway and tumorigenesis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 73-77.
[7]	KAN Jun, ZHOU Daihan, ZHANG Enxin. Research progress in tumor with cardiovascular disease [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 558-561.
[8]	LIU Juan, ZHANG Shutian. Advances in research on the mechanism of cyclin-dependent kinase inhibitor 3(CDKN3)in tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 575-578.
[9]	LI Yue, XU Ke, HAN Zengxiang, SUN Min, FAN Guohua, ZHANG Yong. Advances in the role of tumor-associated macrophage in colon cancer and targeted therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 450-454.
[10]	WANG Yuan, SUN Yihua. Advance in the role of β-catenin in soft tissue tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 455-459.
[11]	ZHANG Yali, SU Danke. Research progress in gadolinium-based molecular probes for tumor targeting imaging [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 460-463.
[12]	HAN Bangling, WANG Yimin, XUE Yingwei. Research progress of vitamin D in tumors of digestive system [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 471-475.
[13]	HAN Bangling,WANG Yimin,XUE Yingwei. Research progress in the relationship between neutrophils and malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 349-352.
[14]	ZHANG Yiyun,WU Huaxing. Progress of metabolic plasticity in tumor growth and metastasis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 362-366.
[15]	WU Qirun,LUO Ting,WANG Peng,XU Ke. Application and prospect of nutritional support in advanced cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 381-384.

Research progress of receptor tyrosine kinase AXL in tumor

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments